Phase I Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®) Administered as Single Bolus Injections or Infusions in Japanese Subjects With Iron Deficiency Anemia
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Iron isomaltoside 1000 (Primary) ; Iron isomaltoside 1000 (Primary)
- Indications Iron deficiency anaemia; Metabolic disorders
- Focus Adverse reactions
- Sponsors Pharmacosmos
- 08 Dec 2017 Status changed from recruiting to completed.
- 02 Feb 2017 Status changed from not yet recruiting to recruiting.
- 09 Jan 2017 New trial record